Home Allakos

Allakos

Actualité internationale

CM – Allakos (ALLK) data are disappointing, Lirentelimab’s future is uncertain – William Blair

Allakos (NASDAQ: ALLK) today released data from ENIGMA 2, a 24-week randomized, double-blind, placebo-controlled phase 3 study of lirentelimab in patients with biopsy-confirmed...

Actualité internationale

CM – Allakos Stock (ALLK): Pourquoi le prix a considérablement chuté aujourd’hui

Le cours de l’action Allakos Inc (NASDAQ : ALLK) – une société de biotechnologie développant le lirentelimab (AK002) pour le traitement des maladies...

Actualité internationale

CM – Allakos reports data from studies on late-stage eosinophilic gastrointestinal diseases

Allakos (ALLK) announces data from ENIGMA 2, a 24-week phase 3 study of lirentelimab in patients with biopsy-confirmed eosinophilic gastritis and / or...